OBJECTIVES: Higher MMF dose can reduce acute GVHD risk after allogeneic hematopoietic cell transplantation (HCT). We examined the effect of MMF dose, relative to patient actual body weight (mg/kg/day), on outcomes of 680 adults after HCT. METHODS: MMF was combined with cyclosporine (n = 599) or sirolimus (n = 81). We divided MMF dose/kg/day in quartiles. RESULTS: The median time to grade II-IV acute GVHD was 32 days. The incidence of grade II-IV acute GVHD at day 30 was 30% in 1st (<29), 20% in 2nd (29-34), 16% in 3rd (35-41), and 19% in 4th (≥42) quartile (P < .01). Corresponding relapse incidence at 1 year was 16%, 25%, 27%, and 31%, respectively (P = .01). In multivariate analysis, as compared to 1st quartile, higher dose of weight-based MMF reduced grade II-IV acute GVHD (HR = 0.64 for 2nd, HR = 0.48 for 3rd, and HR = 0.55 for 4th quartile), but increased the risk of relapse (HR = 1.63 for 2nd, HR = 1.75 for 3rd, and HR = 2.31 for 4th quartile). CONCLUSIONS: Weight-based MMF dose had no significant impact on engraftment, chronic GVHD, or survival. These data suggest that higher weight-based MMF dose reduces the risk of acute GVHD at the expense of increased relapse and supports conducting prospective studies to optimize MMF dosing after HCT.
OBJECTIVES: Higher MMF dose can reduce acute GVHD risk after allogeneic hematopoietic cell transplantation (HCT). We examined the effect of MMF dose, relative to patient actual body weight (mg/kg/day), on outcomes of 680 adults after HCT. METHODS: MMF was combined with cyclosporine (n = 599) or sirolimus (n = 81). We divided MMF dose/kg/day in quartiles. RESULTS: The median time to grade II-IV acute GVHD was 32 days. The incidence of grade II-IV acute GVHD at day 30 was 30% in 1st (<29), 20% in 2nd (29-34), 16% in 3rd (35-41), and 19% in 4th (≥42) quartile (P < .01). Corresponding relapse incidence at 1 year was 16%, 25%, 27%, and 31%, respectively (P = .01). In multivariate analysis, as compared to 1st quartile, higher dose of weight-based MMF reduced grade II-IV acute GVHD (HR = 0.64 for 2nd, HR = 0.48 for 3rd, and HR = 0.55 for 4th quartile), but increased the risk of relapse (HR = 1.63 for 2nd, HR = 1.75 for 3rd, and HR = 2.31 for 4th quartile). CONCLUSIONS: Weight-based MMF dose had no significant impact on engraftment, chronic GVHD, or survival. These data suggest that higher weight-based MMF dose reduces the risk of acute GVHD at the expense of increased relapse and supports conducting prospective studies to optimize MMF dosing after HCT.
Authors: Mohamed L Sorror; Michael B Maris; Rainer Storb; Frederic Baron; Brenda M Sandmaier; David G Maloney; Barry Storer Journal: Blood Date: 2005-06-30 Impact factor: 22.113
Authors: Stephen Harnicar; Doris M Ponce; Patrick Hilden; Junting Zheng; Sean M Devlin; Marissa Lubin; Melissa Pozotrigo; Sherry Mathew; Nelly Adel; Nancy A Kernan; Richard O'Reilly; Susan Prockop; Andromachi Scaradavou; Alan Hanash; Robert Jenq; Marcel van den Brink; Sergio Giralt; Miguel A Perales; James W Young; Juliet N Barker Journal: Biol Blood Marrow Transplant Date: 2015-02-14 Impact factor: 5.742
Authors: Luisa Giaccone; Jeannine S McCune; Michael B Maris; Theodore A Gooley; Brenda M Sandmaier; John T Slattery; Scott Cole; Richard A Nash; Rainer F Storb; George E Georges Journal: Blood Date: 2005-09-06 Impact factor: 22.113
Authors: Mohamed L Sorror; Brent R Logan; Xiaochun Zhu; J Douglas Rizzo; Kenneth R Cooke; Philip L McCarthy; Vincent T Ho; Mary M Horowitz; Marcelo C Pasquini Journal: Biol Blood Marrow Transplant Date: 2015-04-07 Impact factor: 5.742
Authors: Andromachi Scaradavou; Claudio G Brunstein; Mary Eapen; Jennifer Le-Rademacher; Juliet N Barker; Nelson Chao; Corey Cutler; Colleen Delaney; Fangyu Kan; Luis Isola; Chatchada Karanes; Mary J Laughlin; John E Wagner; Elizabeth J Shpall Journal: Blood Date: 2012-12-09 Impact factor: 22.113
Authors: Juliet N Barker; Daniel J Weisdorf; Todd E DeFor; Bruce R Blazar; Philip B McGlave; Jeffrey S Miller; Catherine M Verfaillie; John E Wagner Journal: Blood Date: 2004-10-05 Impact factor: 22.113
Authors: Cara L McDermott; Brenda M Sandmaier; Barry Storer; Hong Li; Donald E Mager; Michael J Boeckh; Meagan J Bemer; Jennifer Knutson; Jeannine S McCune Journal: Biol Blood Marrow Transplant Date: 2013-05-06 Impact factor: 5.742
Authors: Michael B Maris; Dietger Niederwieser; Brenda M Sandmaier; Barry Storer; Monic Stuart; David Maloney; Effie Petersdorf; Peter McSweeney; Michael Pulsipher; Ann Woolfrey; Thomas Chauncey; Ed Agura; Shelly Heimfeld; John Slattery; Ute Hegenbart; Claudio Anasetti; Karl Blume; Rainer Storb Journal: Blood Date: 2003-06-05 Impact factor: 22.113
Authors: Nelli Bejanyan; John Rogosheske; Todd E DeFor; Aleksandr Lazaryan; Mukta Arora; Shernan G Holtan; Pamala A Jacobson; Margaret L MacMillan; Michael R Verneris; Bruce R Blazar; Daniel J Weisdorf; John E Wagner; Claudio G Brunstein Journal: Biol Blood Marrow Transplant Date: 2016-08-09 Impact factor: 5.742